Publisher Full Text
A human monoclonal antibody blocking SARS-CoV-2 infection.Nat Commun. 2020 05 04; 11(1):2251.NC
Abstract
The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.
Links
MeSH
Angiotensin-Converting Enzyme 2AnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntibody AffinityBetacoronavirusCOVID-19Chlorocebus aethiopsConserved SequenceCoronavirus InfectionsCross ReactionsEpitopes, B-LymphocyteHumansIn Vitro TechniquesInhibitory Concentration 50Models, MolecularPandemicsPeptidyl-Dipeptidase APneumonia, ViralProtein BindingProtein DomainsReceptors, VirusSARS VirusSARS-CoV-2Spike Glycoprotein, CoronavirusVero Cells
Pub Type(s)
Journal Article
Research Support, Non-U.S. Gov't
Language
eng
PubMed ID
32366817
Citation
Wang, Chunyan, et al. "A Human Monoclonal Antibody Blocking SARS-CoV-2 Infection." Nature Communications, vol. 11, no. 1, 2020, p. 2251.
Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11(1):2251.
Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R., Osterhaus, A. D. M. E., van Kuppeveld, F. J. M., Haagmans, B. L., Grosveld, F., & Bosch, B. J. (2020). A human monoclonal antibody blocking SARS-CoV-2 infection. Nature Communications, 11(1), 2251. https://doi.org/10.1038/s41467-020-16256-y
Wang C, et al. A Human Monoclonal Antibody Blocking SARS-CoV-2 Infection. Nat Commun. 2020 05 4;11(1):2251. PubMed PMID: 32366817.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - A human monoclonal antibody blocking SARS-CoV-2 infection.
AU - Wang,Chunyan,
AU - Li,Wentao,
AU - Drabek,Dubravka,
AU - Okba,Nisreen M A,
AU - van Haperen,Rien,
AU - Osterhaus,Albert D M E,
AU - van Kuppeveld,Frank J M,
AU - Haagmans,Bart L,
AU - Grosveld,Frank,
AU - Bosch,Berend-Jan,
Y1 - 2020/05/04/
PY - 2020/03/27/received
PY - 2020/04/23/accepted
PY - 2020/5/6/entrez
PY - 2020/5/6/pubmed
PY - 2020/5/7/medline
SP - 2251
EP - 2251
JF - Nature communications
JO - Nat Commun
VL - 11
IS - 1
N2 - The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.
SN - 2041-1723
UR - https://www.unboundmedicine.com/medline/citation/32366817/full_citation
L2 - https://doi.org/10.1038/s41467-020-16256-y
DB - PRIME
DP - Unbound Medicine
ER -